Thermo Fisher Scientific Expands Viral Vector Manufacturing at Plainville, Massachusetts, Facility
05/12/2020
According to company officials, the $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines.
Construction of the new 290,000-square-foot facility is expected to be completed in 2022. The project will add more than 200 jobs and complement the company's new or recently expanded capacity in Lexington and Cambridge, Massachusetts, and Alachua, Florida.
"The Plainville expansion significantly enhances our 'start here, stay here' strategy, ensuring that customers have an uninterrupted pathway from development through commercialization," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "Between Plainville and our other expanded sites in the U.S., we're increasing viral vector production to accelerate cell and gene therapy innovation, giving hope to more patients everywhere."
The Plainville site will offer a flexible and scalable configuration of laboratory and production suites co-located with adjacent warehousing and office space. An onsite engineering laboratory will help customers develop turnkey production platforms that enable them to rapidly transition to commercial-scale operations when ready. As with its other viral vector development and manufacturing sites, Thermo Fisher's Plainville site will attract a diverse workforce of scientists, quality control specialists and production teams.
Thermo Fisher strategically selected Plainville to capitalize on its expertise at other Massachusetts locations and draw upon the strong talent pool in the Greater Boston area. The state-of-the-art facility will feature digital connectivity and capabilities that enable operational efficiencies, high quality, data visibility and advanced operator training.
Lagarde added, "The global race to develop new transformative medicines illustrates how important it is for our customers to have access to surge capacity as well as flexibility to adapt and change therapeutic platforms, whether they are developing a new viral vector for a novel therapy or the next life-saving cancer treatment."
Project Announcements
US Forged Rings Plans Hertford County, North Carolina, Steel Component Operations
03/02/2026
South Korea-Based Hanjung America Plans Huntington, Indiana, Manufacturing Operations
03/02/2026
Faith Technologies Plans Opelika, Alabama, Manufacturing Operations
03/01/2026
TaylorMade Golf Expands Vanderburgh County, Indiana, Distribution Operations
03/01/2026
Sediver USA Expands West Memphis, Arkansas, Operations
03/01/2026
Carpenter Pole and Piling Expands Wiggins, Mississippi, Operations
03/01/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
The New Industrial Revolution in Biotech
Q4 2025
-
Strategic Industries at the Crossroads: Defense, Aerospace, and Maritime Enter 2026
Q1 2026
-
The Skilled Trades Are Ready for a Digital Future
Q4 2025
-
Amazon’s First Mass Timber Delivery Station Tests the Future of Low-Carbon Logistics
Q4 2025